Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications in Health Policy
Pnd42 - Burden of Multiple Sclerosis in Russia and Europe
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy39 - Quantifying Worldwide Evidence to Estimate the Risk of Transmitting Creutzfeldt-Jakob Disease via Surgical Procedures
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Php310 - Comparison of the Health Technology Assessment Offices of Hungary and Poland Based on Objective Criteria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Php329 - The Registry Evaluation and Quality Standards Tool (Request) for Health Technology Assessment From an Outcomes Assessment Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pin110 - Comparison of Drug Assessment Reports Published by French (Has-Ceesp) and Uk (Nice) Htas: Focus on Hepatitis C
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss14 - Budget Impact Analysis of Conbercept and Ranibizumab in Patients With Wet Age-Related Macular Degeneration in China
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy83 - Impact of Dose Escalation on Average Cost and Cost-Effectiveness of Anti-TNF and Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Sweden
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Black Box Amnog Rebates: What Is Driving the Price in the Negotiation With the GKV-Spitzenverband?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn102 - Extra-Cost of Brain Metastases in Patients With Non-Squamous Non-Small Cell Lung Cancer (Nsclc) : A French National Hospital Database Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prm142 - Quantitative Benefit-Risk Modelling of Biosimilars: A Case Study of Infliximab in Crohn’s Disease.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
‹
452
453
454
455
456
457
458
›
